Hidradenitis suppurativa (HS) is known to increase the risk of diabetes mellitus. This study aims to compare rates and outcomes of 30-day readmissions following admissions for type 1 diabetic ketoacidosis (T1DKA) in patients with and without co-existing Hidradenitis Suppurative (HS) in the United States.

We analyzed the 2018 National Readmission Database. We included index hospitalizations for all patients (aged≥18 years) with a principal diagnosis of T1DKA using ICD-10 codes. We further sub-stratified this group into those with and with a secondary diagnosis of HS. Chi-square tests and regression analysis were used to compare rates and outcomes of 30-day readmissions between both groups. We excluded elective and traumatic readmissions.

A total of 94,461 index hospitalizations for T1DKA, that were discharged alive, were included in the analysis. 109 (0.2%) of these, had co-existing HS. A total of 15,614 (16.5%) readmissions occurred within 30 days. Readmission rates were similar between HS and non-HS group (21.8% vs. 16.5%, p=0.328). HS group had a similar mean hospital length of stay (3.0 days vs. 2.9 days, p=0.645) and mean total hospital costs ($6,878 vs. $7,236, p=0.691) compared to the non-HS group. Readmissions for T1DKA in HS patients were associated with a total of 331 hospital days and $747,976 in hospital costs. T1DKA without coma was the most common reason for readmission in both groups.

HS patients admitted for T1DKA have a greater, but statistically non-significant rate of 30-day readmission, and similar readmission outcomes compared to non-HS patients admitted for TIDKA.

Disclosure

E. Edigin: None. H. Shaka: None. P. O. Eseaton: None. M. Almani: None. A. Kichloo: None. P. E. Ojemolon: None. D. Jakhar: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.